Oruka Therapeutics to Present at Multiple November Investor Conferences
Oruka Therapeutics (Nasdaq: ORKA), a biotech company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, has announced its participation in two major investor conferences in November 2024. The company will present at the Stifel 2024 Healthcare Conference on November 18th at 2:25PM ET and the Jefferies London Healthcare Conference on November 20th at 2:00PM GMT. Webcasts and replays of the presentations will be accessible through Oruka's investor events website.
Oruka Therapeutics (Nasdaq: ORKA), una compagnia biotecnologica focalizzata nello sviluppo di nuovi biologici per malattie croniche della pelle, tra cui la psoriasi a placche, ha annunciato la sua partecipazione a due importanti conferenze per investitori a novembre 2024. L'azienda presenterà alla Stifel 2024 Healthcare Conference il 18 novembre alle 14:25 ET e alla Jefferies London Healthcare Conference il 20 novembre alle 14:00 GMT. I webcast e le registrazioni delle presentazioni saranno accessibili attraverso il sito web degli eventi per investitori di Oruka.
Oruka Therapeutics (Nasdaq: ORKA), una empresa biotecnológica centrada en el desarrollo de nuevos biológicos para enfermedades crónicas de la piel, incluyendo la psoriasis en placas, ha anunciado su participación en dos importantes conferencias para inversores en noviembre de 2024. La compañía presentará en la Stifel 2024 Healthcare Conference el 18 de noviembre a las 2:25 PM ET y en la Jefferies London Healthcare Conference el 20 de noviembre a las 2:00 PM GMT. Las transmisiones web y las repeticiones de las presentaciones estarán disponibles a través del sitio web de eventos para inversores de Oruka.
오루카 테라퓨틱스 (Nasdaq: ORKA)는 판상 건선과 같은 만성 피부 질환을 위한 새로운 생물학적 제제를 개발하는 데 중점을 둔 생명공학 회사로, 2024년 11월에 두 건 주요 투자자 컨퍼런스에 참가한다고 발표했습니다. 이 회사는 11월 18일 동부 표준시로 오후 2시 25분에 Stifel 2024 Healthcare Conference에서 발표하고, 11월 20일 그리니치 표준시로 오후 2시에 Jefferies London Healthcare Conference에서 발표할 예정입니다. 발표의 웹캐스트와 다시 보기 자료는 오루카의 투자자 이벤트 웹사이트를 통해 접근할 수 있습니다.
Oruka Therapeutics (Nasdaq: ORKA), une entreprise biopharmaceutique axée sur le développement de nouveaux produits biologiques pour les maladies chroniques de la peau, y compris le psoriasis en plaques, a annoncé sa participation à deux grandes conférences pour investisseurs en novembre 2024. L'entreprise fera une présentation lors de la Stifel 2024 Healthcare Conference le 18 novembre à 14h25 ET et à la Jefferies London Healthcare Conference le 20 novembre à 14h00 GMT. Les webcasts et les rediffusions des présentations seront accessibles via le site des événements pour investisseurs d'Oruka.
Oruka Therapeutics (Nasdaq: ORKA), ein Biotechnologieunternehmen, das sich auf die Entwicklung neuartiger biologischer Präparate für chronische Hauterkrankungen, einschließlich Plaque-Psoriasis, konzentriert, hat seine Teilnahme an zwei bedeutenden Investorenkonferenzen im November 2024 angekündigt. Das Unternehmen wird auf der Stifel 2024 Healthcare Conference am 18. November um 14:25 Uhr ET und auf der Jefferies London Healthcare Conference am 20. November um 14:00 Uhr GMT präsentieren. Webcasts und Wiederholungen der Präsentationen werden über die Investor-Events-Website von Oruka zugänglich sein.
- None.
- None.
MENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:
Stifel 2024 Healthcare Conference
Date: Monday, November 18th, 2024
Time: 2:25PM ET
Jefferies London Healthcare Conference
Date: Wednesday, November 20th, 2024
Time: 2:00PM GMT
A webcast and replay of Oruka’s presentation will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
FAQ
When is Oruka Therapeutics (ORKA) presenting at the Stifel Healthcare Conference in 2024?
What time is Oruka Therapeutics (ORKA) presenting at the Jefferies London Healthcare Conference in 2024?
Where can investors watch Oruka Therapeutics' (ORKA) November 2024 conference presentations?
What therapeutic areas does Oruka Therapeutics (ORKA) focus on?
